Form 4: Achieve Life Sciences Director Granted 31,500 Stock Options

Achieve Life Sciences, Inc. has reported that Director Thomas Braxton King was granted 31,500 stock options with an exercise price of $3.83 per share, vesting in 2026.

Summary

• Thomas Braxton King, a Director of Achieve Life Sciences, Inc. (ACHV), was granted 31,500 stock options.
• The options have an exercise price of $3.83 per share.
• The transaction date for the grant was June 6, 2025.
• These options are set to expire on June 6, 2035.
• The options will vest 100% on the earlier of June 6, 2026, or the date immediately prior to the Issuer's 2026 annual meeting of stockholders.
• Following this transaction, Thomas Braxton King directly beneficially owns 31,500 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. A stock option grant to a director is a standard practice that aligns management incentives with shareholder value. It's not a major catalyst but indicates ongoing compensation and commitment.

Positives

• The grant of stock options to a director aligns the director's interests with those of shareholders, as the options gain value if the company's stock price increases.
• The vesting schedule encourages long-term commitment and performance from the director.

Negatives

• The exercise price of $3.83 per share means the stock price must rise above this level for the options to be in-the-money, representing a potential dilution if exercised in the future.

Future Outlook

The stock options granted to Director Thomas Braxton King are scheduled to vest 100% on the earlier of June 6, 2026, or the date immediately prior to the Issuer's 2026 annual meeting of stockholders, indicating a future milestone for the director's equity compensation.

Industry Context

This Form 4 filing represents a routine equity compensation event for a director in the biotechnology or pharmaceutical industry, a common practice to incentivize leadership and align their interests with long-term company performance. Such grants are standard components of executive and director compensation packages across various industries.

Comparison to Industry Standards

• The grant of stock options to directors is a common practice in publicly traded companies, particularly in the life sciences sector, to attract and retain talent and align interests with shareholders.
• The specific number of options (31,500) and the exercise price ($3.83) would need to be compared against similar-sized companies in the biotechnology industry and their director compensation policies to assess if it's within typical ranges. Without specific comparable company data, a direct assessment against global benchmarks is limited, but the mechanism itself is standard.

Related Party Transactions

• The grant of stock options to Thomas Braxton King, a Director, constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the options become more valuable if the stock price increases. However, potential future exercise could lead to minor dilution.
• Employees: No direct impact mentioned for general employees.
• Management/Directors: Thomas Braxton King receives additional equity compensation, incentivizing his continued contribution to the company's success.

Next Steps

• The options will vest 100% on the earlier of June 6, 2026, or the date immediately prior to the Issuer's 2026 annual meeting of stockholders.

Key Dates

Recommendation

Keywords

Achieve Life Sciences, ACHV, Stock Options, Form 4, Insider Transaction, Director Compensation, Equity Grant, SEC Filing